TDOC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Teladoc Health Inc (TDOC) is not a good buy for a beginner investor with a long-term strategy at this time. The company's financial performance is weak, with declining net income, EPS, and gross margin. Analysts have significantly lowered price targets, reflecting concerns about the company's growth and strategic challenges. Additionally, there are no strong positive catalysts or trading signals to justify an immediate purchase.
The MACD is positive but contracting, RSI is neutral at 56.622, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 4.985, with resistance at 5.374 and support at 4.596. The technical indicators suggest a lack of strong momentum in either direction.
The company reported better-than-expected Q4 results in terms of adjusted EBITDA and revenue. Analysts like Canaccord maintain a Buy rating, citing valuation as a potential positive factor.
Analysts have broadly lowered price targets, citing concerns about Teladoc's ability to evolve in a competitive market. The company's FY26 guidance is below Street expectations, and there are concerns about pricing power and gross margin pressure. Additionally, no significant insider or hedge fund activity has been observed.
In Q4 2025, revenue grew marginally by 0.28% YoY to $642.27M, but net income dropped by -48.06% YoY to -$25.14M. EPS declined by -50.00% YoY to -0.14, and gross margin fell by 3.50% YoY to 54.55%. These metrics indicate financial struggles and declining profitability.
Analyst sentiment is generally cautious. Multiple firms, including Oppenheimer, Citi, UBS, and Evercore, have significantly lowered their price targets, with most ratings being Neutral or Hold. Only a few firms, such as Canaccord and Piper Sandler, maintain Buy or Overweight ratings, but even they acknowledge challenges in the company's growth trajectory.
